An observational study in Prostatic Neoplasms, sponsored by Swiss Group for Clinical Cancer Research. Active, not recruiting at 12 sites in Switzerland. Open to male participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-08.
Sponsored by Swiss Group for Clinical Cancer Research · Observational
Carcinoma of the prostate is the second most commonly diagnosed cancer and occurs predominantly in older men - almost two-thirds of those affected are over 65 years of age. In a significant proportion of patients, the disease is harmless and progresses only very slowly. As a result, there is a risk of overdiagnosis and overtreatment. The main diagnostic tool for prostate cancer is the prostate-specific antigen (PSA) test, but its specificity is minimal. It is important to look for other biological characteristics (biomarkers) that provide pointers to the need for a diagnosis and treatment. Even after treatment and in advanced stages of disease, decisions are often difficult, because it is not necessarily clear which patient needs a specific treatment.
In this study, a multicenter biobank of patient sera, plasma and tissue is being established together with information of relevance to the disease, in order to provide a basis for the testing of biomarkers. The aim is to identify markers that offer diagnostic and treatment-selective pointers and thus make a decisive contribution to the optimum care of patients.
Background \& Rationale:
Prostate Cancer (PCa) occurs mainly in older men, nearly two thirds are diagnosed in men aged 65 or older. However, in a substantial subset of patients, the disease will be slow-growing and harmless. This highlights one of the major issues with PCa screening and diagnosis: the risks of over-detection and overtreatment, i.e. to diagnose and invasively treat indolent cancers that may lead to reduced quality of life without increasing overall survival.
The main diagnostic tool for PCa is the systematic screening for PSA (prostate-specific antigen), despite the low specificity of PSA and the unclear cut-off value, resulting in a large proportion of unnecessary biopsies with potential side effects. Additionally, as screening addresses a healthy population and screened men may suffer from disadvantages, such as unnecessary biopsies, screening in PCa remains controversial.
Besides the dilemmas in PCa screening, there are several additional important clinical questions that deserve further investigation and better risk-adapted patient stratification as follows: 1) active treatment versus deferred therapy in the heterogeneous group of patients with localized PCa; 2) treatment intensification for locally-advanced, high-risk prostate cancers with significant risk of PCa-related deaths; 3) optimal approach for patients with high risk of local recurrence post-radical prostatectomy; 4) treatment of patients with rising PSA (biochemical relapse) after curative treatment (either radical prostatectomy or RT); 5) a better understanding of oligometastatic disease and; and 6) treatment of patients with castration-resistant prostate cancer (CRPC).
PCa is characterized by a wide spectrum of molecular and phenotypic characteristics. PCa patients are currently grouped in different risk categories, illustrating particular features of a heterogeneous disease. On one side, many patients present benign disease, such as benign prostate enlargement caused by prostate hyperplasia and, on the other side, progressively malignant PCa, ranging from localized, locally-advanced, metastatic and castrate-resistant disease.
For the purpose of this study, we established 5 groups and their corresponding subgroups, as follows:
A) Opportunistic screening and benign prostate syndrome (BPS) with prostate biopsy; B) Localized and locally advanced prostate cancers treated with curative intent; C) Biochemical relapse after RP; D) Metastatic advanced PCa without curative treatment but hormone sensitive disease, treated with ADT (medical or surgical); E) Metastatic castration resistant prostate cancer (mCRPC).
Currently a comprehensive biobank in the field of urogenital disease, driven by a multidisciplinary panel (composed by specialists from the following fields: urology, medical oncology, radio-oncology and pathology), does not exist in Switzerland.
Such biobank (together with the corresponding clinical data) would enable researchers and clinicians alike to discover and validate diagnostic, prognostic and predictive PCa biomarkers, which are currently highly needed.
Importantly, the biobank shall consist of specific sample sets related to the different stages of PCa development (including screened healthy men and newly diagnosed patients). Ultimately, this comprehensive project will allow addressing some of the urgent questions in different stages of PCa.
Objective:
To create a novel and comprehensive plasma and serum biobank of about 55000 samples (derived from about 1540 patients) accompanied by the corresponding clinical data. This will enable us to explore and validate different diagnostic, prognostic and predictive biomarkers regarding prostate disease.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's enrollment of 1,323 is above the median of 200 across 1,181 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Swiss Group for Clinical Cancer Research is the lead sponsor of 107 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
See description under "Groups/Cohorts"
Criteria for entering diagnostic group A
Criteria for entering group B
Subgroup B0 (active surveillance, closed group):
All of the following criteria should be fulfilled:
Subgroups B1-B3 (treatment with curative intent):
Criteria for entering diagnostic group C
Criteria for entering diagnostic group D
Criteria for entering diagnostic group E (metastatic castration resistant PCa)
Exclusion criteria:
Asymptomatic men offered screening (PSA testing) with prostate biopsy (A1). Or patients with lower urinary tract symptoms from benign prostatic hyperplasia undergoing: no treatment (A2), medical therapy (A3), or transurethral resection of the prostate (A4)
Other: Observation
B0: Patients under active surveillance (B0, closed group); B1: radical prostatectomy (RP) or RP followed by (adjuvant) external beam radiation; B2: external beam radiation therapy (EBRT) without androgen deprivation therapy (ADT); B3: external beam radiation therapy with ADT
Other: Observation
Patients with PSA progression after RP with or without systemic therapy
Other: Observation
Metastatic PCa without curative treatment but hormone sensitive disease, treated with ADT (medical or surgical), with or without additive treatments. Oligometastatic PCa.
Other: Observation
Metastatic castration resistant prostate cancer (mCRPC). Oligometastatic PCa.
Other: Observation
Group A: Time to prostate cancer (PCa) histological diagnosis
Time to PCa histological diagnosis will be calculated from the time when patients were assigned into group A until documentation of a positive biopsy result.
Time frame: At the occurrence of a positive biopsy result or latest 10 years after registration
Group B0: Progression free survival (PFS)
PFS will be calculated from the time when patients were assigned into group B0 until first documented event occurred: * three or more positive cores at rebiopsy * Gleason score ≥ 7 at rebiopsy
Time frame: At 1 year after assigned into Group B0
Group B1: Biochemical relapse free survival
Biochemical relapse free survival is calculated from the time when patients were assigned into group B1 until prostate specific antigen (PSA) relapse occurs. PSA relapse is defined as PSA progression after radical prostatectomy (RP) is defined as two consecutive rises with the final PSA value \> 0.1 ng/mL, or three consecutive rises (the first value must be measured earliest 4 weeks after RP).
Time frame: At 5 years after assigned into Group B1
Group B2-B3: Interval to biochemical failure (IBF)
IBF is defined as the time interval from completion of treatment by patients of group B2 or B3 until biochemical failure (BF). BF is defined by an absolute PSA value superior or equal to the post-treatment PSA nadir + 2 ng/mL.
Time frame: At 18 months after assigned into Group B2-B3
Group C: Progression free survival (PFS)
PFS is counted from the day the patient entered group C to the day of the first record of either local or regional recurrence, distant recurrence, start of hormonal treatment after biochemical failure, or death due to any cause.
Time frame: At progression or latest 10 years after assigned into Group C
Group D: Biochmical prostate specific antigen progression
The biochemical prostate specific antigen (PSA) progression is calculated from the induction of palliative androgen deprivation therapy (ADT), defined as: * In case PSA levels had not decreased from baseline, under treatment: ≥ 25% increase from baseline (last PSA measurement before treatment start) AND an increase in the absolute PSA value of ≥ 2 ng/mL and presence of castrate level of testosterone. * In case PSA levels decreased from baseline, under treatment: ≥ 25% increase above the nadir AND an increase in the absolute PSA value of ≥ 2 ng/mL and presence of castrate level of testosterone.
Time frame: At 6 months after induction of androgen deprivation therapy
Group E: Overall survival (OS)
OS will be calculated from the time when patients were assigned into group E until death from any cause. OS will be censored at the time the patient is last known to be alive if: * the patient is lost to follow-up * or death is not experienced.
Time frame: At death or latest 10 years after assigned into Group E
Group A, B0-B3, C, D: Overall survival (OS)
OS will be calculated from the time when patients were assigned into the group until death from any cause. OS will be censored at the time the patient is last known to be alive if: * the patient is lost to follow-up * or death is not experienced.
Time frame: At death from any cause or latest 10 years after assigned into the corresponding Group
Group A, B1-B3, C: Time to PCa-specific death
Time to PCa-specific death is calculated from the time when patients were assigned into the group until death due to cancer occurs.
Time frame: At prostate cancer related death or latest 10 years after assigned into the corresponding Group
Group B0: Progression free survival (PFS)
PFS will be calculated from the time when patients were assigned into group B0 until first documented event occurred: * three or more positive cores at rebiopsy * Gleason score ≥ 7 at rebiopsy * after follow-up ≥ 1 year: PSA doubling time \<3 years
Time frame: At the occurrence of the event or latest 10 year after assigned into Group B0
Group B0: Event free survival (EFS)
EFS will be calculated from the time when patients were assigned into group B0 until documented events, whichever occurs first: * Any criteria defining PFS, and in addition the following ones: * transurethral resection * RP with curative intent * RT with curative intent * start of androgen deprivation therapy (ADT)
Time frame: At the occurrence of the event or latest 10 year after assigned into Group B0
Group D: Progression free survival (PFS)
PFS is calculated from the time when patients were assigned into group D until documentation of one or any combination of the following events occurred: * Biochemical PSA progression * Progression of metastatic disease * symptomatic clinical progression * death
Time frame: At the occurrence of the event or latest 10 year after assigned into Group D
Group E: Progression free survival (PFS)
PFS will be calculated from the time when patients were assigned into group E until disease progression or death.
Time frame: At the occurrence of the event or latest 10 year after assigned into Group E
Plan to share: Yes — Data may be shared on reasonable request, after internal and ethical approval
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Swiss Group for Clinical Cancer Research